Reflectance Confocal Microscopy to diagnose malignant melanoma and lentigo maligna: HS-MAV-002

CHIEF INVESTIGATOR:
Howard Stevens, MA (Oxon); MBBS; FRCP, PhD. Consultant Dermatologist,

Address and contact details:
Skin Care Network
3 Church Passage
Wood Street
Barnet EN5 4QS

Sponsor:
Medical Advisory Committee (MAC)
Skin Care Network Barnet Ltd
3 Church Passage
Wood Street
Barnet
EN5 4QS
Contents

Protocol Synopsis .................................................................................................................................. 3
Study Title: ............................................................................................................................................. 4
Background ............................................................................................................................................ 4
Aims........................................................................................................................................................ 5

Study Design and Methods .................................................................................................................... 5
  Study Design.................................................................................................................................. 5
  Study Hypothesis ........................................................................................................................... 5
  Setting ............................................................................................................................................ 5
  Participants .................................................................................................................................... 5
  Exclusion criteria............................................................................................................................ 5
  Informed Consent ............................................................................................................................... 5
  Study Intervention .............................................................................................................................. 6

Statistics................................................................................................................................................. 7
  Summary of statistical methods: ........................................................................................................ 7
  Sample size calculation .................................................................................................................... 7

Data management and analysis............................................................................................................. 8

Ethical Issues ......................................................................................................................................... 9
  Amendments .................................................................................................................................. 9
  Annual Progress Report .................................................................................................................. 9
  End of study report ........................................................................................................................... 9

Public disclosure and publication policy.............................................................................................. 9

Safety Considerations.......................................................................................................................... 10
  Adverse and Serious Adverse Events (SAE) .................................................................................. 10
  Follow-up of adverse events ............................................................................................................ 10
  Data Safety Monitoring Board ........................................................................................................ 10

Sponsorship & Indemnity ..................................................................................................................... 10

Publication Policy ................................................................................................................................ 11

Data Safety Monitoring Board ........................................................................................................... 11

References: .......................................................................................................................................... 11

Appendix 1: Patient Information Sheet ................................................................................................ 11
Appendix 2: Patient Consent Form ........................................................................................................ 11
# Protocol Synopsis

<table>
<thead>
<tr>
<th>Protocol ID</th>
<th>Version 0.4. 8  February 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Protocol Title</td>
<td>HS-MAV-002</td>
</tr>
<tr>
<td>Development phase</td>
<td>II</td>
</tr>
<tr>
<td>Primary endpoint</td>
<td>Specificity &amp; Sensitivity of RCM in diagnosing adult MM and LM compared to standard histology</td>
</tr>
<tr>
<td>Secondary endpoint</td>
<td>Inter- &amp; intra-observer agreement in assessing RCM images. Time taken for in-vivo examination of lesion.</td>
</tr>
<tr>
<td>Study design</td>
<td>This is an observational, non-randomised, non-controlled, prospective cohort study to look at the efficacy of <em>in vivo</em> RCM as a diagnostic tool in the diagnosis of MM and LM.</td>
</tr>
<tr>
<td>Key Inclusion Criteria</td>
<td>Patients 18 years or older with a suspected diagnosis of MM or LM</td>
</tr>
<tr>
<td>Key Exclusion Criteria</td>
<td>Recurrent MM or LM Patient on immunosuppressants Patient with significant co-morbidity or skin disease Patient not suitable for diagnostic biopsy Location of lesion unsuitable, inaccessible or impractical for scanning with RCM as determined by investigator</td>
</tr>
<tr>
<td>Patient Accrual</td>
<td>Up to 700 Patients over 18 months</td>
</tr>
<tr>
<td>Protocol follow-up procedure</td>
<td>None</td>
</tr>
<tr>
<td>Chief Investigator</td>
<td>Dr Howard Stevens</td>
</tr>
<tr>
<td>Co-Investigators</td>
<td>Prof Giovanni Pellacani, University of Modena</td>
</tr>
<tr>
<td>Other key staff</td>
<td>Dr Ioulios Palamaras Dermatologist</td>
</tr>
<tr>
<td>Host Institution</td>
<td>Skin Care Network Barnet</td>
</tr>
<tr>
<td>Funding</td>
<td>None</td>
</tr>
</tbody>
</table>

---

*HS-MAV-002 Protocol version 0.4*

28/02/2017
Study Title:

Reflectance Confocal Microscopy to diagnose adult malignant melanoma and lentigo maligna: HS-MAV-002

Background

Pigmented lesions suspicious for Malignant Melanoma (MM), Spitz naevi, Spitzoid melanoma or Lentigo Maligna (LM) can be challenging to diagnose. Both visual and dermatoscopic diagnostic performance of clinicians is highly variable and highly dependent on clinician training, and the number of lesions needed to excise to find one cancerous lesion (NNE) can be 14 or higher [1].

Reflectance confocal microscopy (RCM) is a high resolution, non-invasive method for visualising skin in cellular detail in-vivo, and has been shown to be diagnostic for MM and LM in adult populations. Meta-analysis has shown a per lesion sensitivity of 93% [95% CI 89–96] and a specificity of 76% [95% CI 68–83] for MM in equivocal lesions [2].

Current guidelines assume that only dermatoscopically equivocal lesions are examined using RCM, and that the potential for RCM to impact sensitivity is therefore very limited [3]. However, RCM can significantly help with equivocal lesions, with a sensitivity of 100% and a specificity of 69%, avoiding 35 of the 51 nevi in one study [4]. A recent paper showed the number needed to excise (NNE) reduced from 14.6 to 6.8 with the addition of RCM [1].

At the Royal Free Hospital they currently surgically excise approximately 100 MM and LM each year. Because of the dangerous nature of the disease, it is very important that no MM lesions are missed. This leads to a requirement to biopsy a large number of benign lesions to ensure that sensitivity is maintained at as close to 100% as possible. The NNE measure describes this, detailing the number of lesions excised in order to find one malignant lesion.

Recently, NICE guidance (Nov 2015) was issued regarding the use of RCM in the management of skin cancer [5]. They concluded the following:

“The VivaScope 1500 and 3000 imaging systems show promise but there is currently insufficient evidence to recommend their routine adoption in the NHS…”

“Further research...on using the VivaScope 1500 and 3000 imaging systems is recommended in the following areas:

…the impact on clinical workflows for melanoma and basal cell carcinoma assessment in secondary care settings.

…the number of confirmatory diagnostic biopsies needed for people with a clinical diagnosis of melanoma before definitive treatment is started.”

Both instruments are available for this study, and either / both will be used depending on anatomic considerations. This would be the first study in the UK assess the use of reflectance confocal microscopy in the diagnosis of MM and LM. If RCM is able to accurately diagnose melanoma in a significantly higher proportion of patients then Number of benign lesions Needed to Excise (NNE) to find a MM or LM might reasonably be reduced by 30% from its current value of approximately 10.
Aims

We propose to undertake a study to determine the diagnostic utility of using the RCM for the
diagnosis of adult Malignant Melanoma (MM), Spitz naevi, Spitzoid melanoma and Lentigo Maligna
(LM) in a tertiary referral centre as outlined by the recent NICE report (Nov 2015).

Study Design and Methods

Study Design

This is an observational, non-randomised, non-controlled, prospective cohort study to look at the
efficacy of in vivo RCM as a diagnostic tool in the diagnosis of MM and LM.

Study Endpoints

The hypothesis of this study is that the use of RCM is would reduce the NNE prior to definitive
treatment by at least 30% from the current value of approximately 10.

The secondary hypothesis is that the intra- & inter-observer agreement for interpreting the RCM
images will have kappa scores 0.6 or greater (indicating good agreement).

Setting and recruitment

Patients will be recruited from the outpatient clinics of the Skin Care Network Barnet.

Participants

The number of true negative lesions examined in this study will be 654. It is anticipated that this will
result in a total of 661 lesions being recruited. 10% of participants are expected to have more than
one lesion sampled.

The result of biopsy for each lesion will not be known until after the lesion has been included in the
study. Therefore lesions will be added to the study until the required number of true negatives has
been included.

Recruits must fit the following criteria:

1. Age 18 years or older
2. Patient with a pigmented lesion recommended for excision because of suspicion of MM or
   LM.
3. Patient willing and able to give informed consent

Exclusion criteria

1. Recurrent MM or LM
2. Patient on immunosuppressants
3. Patient with significant co-morbidity or skin disease
4. Patient not suitable for diagnostic biopsy
5. Location of lesion unsuitable, inaccessible or impractical for scanning with RCM as
determined by investigator

Informed Consent

The Investigator, or an authorised member of their team, will obtain written informed consent for
patients. It is anticipated that patients will be approached regarding participation after diagnosis
when they have been identified as having an equivocal pigmented lesion requiring biopsy under
standard of care.
When obtaining informed consent, investigators must ensure that they adequately explain the aim, anticipated benefits and potential hazards of taking part in the trial to the patient. Investigators should also stress that patients are free to refuse to take part or withdraw from the trial at any time. The patient should be given ample time to read the appropriate patient information sheet and to discuss their participation with others if requested. The patient must be given an opportunity to ask questions which should be answered to their satisfaction. The right of the patient to refuse to participate in the trial without giving a reason must be respected.

Patients who agree to take part should be asked to sign and date the latest version of the consent form. The Investigator, or an authorised member of their team, must then sign and date the form. A copy of the consent form should be given to the patient, a copy should be filed in the clinical notes, and the original placed in the site file.

**Study Intervention**

Patients will be assessed in clinic by a consultant dermatologist. Patients with an equivocal pigmented lesion will be invited to participate. Clinical and dermoscopic images will be taken by the team as part of their routine standard of care. Patients will be invited to participate in the trial and provided with a patient information leaflet. They will be given sufficient time to review the information sheet and ask questions.

Patients will be consented to having confocal microscopy performed of the target lesion before undergoing biopsy for histology. Acceptable biopsy methods will include punch, shave or excision biopsy with the intention of providing a diagnosis. These patients would be having photographs, including dermoscopic images, and a biopsy as part of their standard of care, therefore the only additional intervention is examination with the confocal microscope.

Confocal microscopy will be performed by a trained clinician, either a doctor or nurse specialist. Once the operator is satisfied that all images (clinical, dermoscopic and confocal) have been taken to a standard that will allow independent assessors to provide a diagnosis, they will be stored on a secure server and indexed anonymously with reference to the subject’s assigned unique trial number. Imaging time is expected to last approximately 15-20 mins per patient. In this way, data will be anonymised to allow blinding of the diagnosis with reference to the images during the analysis phase. The trial co-ordinator will be responsible for maintaining the database containing the patient and lesion information in addition to the images. The co-ordinator will be the only unblinded member of the investigatory team.

The images taken of the tumour by the confocal microscope system will be anonymised. Imaging will include clinical imaging on an area of 30x30 to 50x50 cm², centred around the lesion of concern, a close up image of the lesion, and the high-resolution picture of the lesion. The clinical picture will be masked appropriately to preserve patient anonymity.

These images will then be examined by a different dermatologist who has undergone training in examining confocal images. The images will also be sent to a dermatologist in Modena who is an expert in interpreting confocal microscopic images – both of these dermatologists will be blinded as to the patient’s history and the results of the diagnostic biopsy except age, sex and relevant information concerning lesion history and changes. The clinicians interpreting the confocal microscope images will be asked to complete the following questions:

1. **RCM description**: features of MM / LM.
2. **RCM diagnosis**: MM / LM (Y/N); degree of certainty (0=low; 1=possible; 2=almost certain)
3. **RCM quality of imaging**: 0=low/don’t feel confident; 1=acceptable/could be improved; 2=high quality (free text for images scoring 0)

The biopsies will undergo routine processing in our histopathology laboratory as normal and will be analysed by a pathologist who will be unaware of the findings on confocal microscopy.
Statistics

Summary of statistical methods:

The primary hypothesis of this study is that the use of RCM is would reduce the number needed to excise (NNE) prior to definitive treatment by at least 30% from the current value of approximately 10. The secondary hypothesis is that the intra- & inter-observer agreement for interpreting the RCM images will have kappa scores 0.6 or greater (indicating good agreement).

The 95% confidence interval for the specificity and sensitivity will be calculated for both observers. The NNE will also be reported along with a 95% confidence interval.

To assess the inter-observer agreement the Kappa statistic will be reported alongside the proportion of agreements and disagreements.

Sample size calculation

The sample size has been determined in terms of the number of lesions examined, and assumes that lesions within a patient are independent.

Table 1 shows the relationship between the NNE and the specificity, assuming 100% sensitivity, for two values of the percentage positive in the population. For example if there are 5% positive lesions in the population of equivocal lesions and if NNE is to be 6, the specificity must be 74%. If the proportion of positive lesions is lower (2%) then a higher specificity is required to achieve each NNE value.

<table>
<thead>
<tr>
<th>% true P</th>
<th>N/P</th>
<th>NNE</th>
<th>Specificity</th>
</tr>
</thead>
<tbody>
<tr>
<td>2%</td>
<td>49</td>
<td>6</td>
<td>90%</td>
</tr>
<tr>
<td>2%</td>
<td>49</td>
<td>7</td>
<td>88%</td>
</tr>
<tr>
<td>2%</td>
<td>49</td>
<td>8</td>
<td>86%</td>
</tr>
<tr>
<td>2%</td>
<td>49</td>
<td>10</td>
<td>82%</td>
</tr>
<tr>
<td>2%</td>
<td>49</td>
<td>15</td>
<td>71%</td>
</tr>
<tr>
<td>5%</td>
<td>19</td>
<td>6</td>
<td>74%</td>
</tr>
<tr>
<td>5%</td>
<td>19</td>
<td>7</td>
<td>68%</td>
</tr>
<tr>
<td>5%</td>
<td>19</td>
<td>8</td>
<td>63%</td>
</tr>
<tr>
<td>5%</td>
<td>19</td>
<td>10</td>
<td>53%</td>
</tr>
<tr>
<td>5%</td>
<td>19</td>
<td>15</td>
<td>26%</td>
</tr>
</tbody>
</table>

The numbers of lesions required to provide a lower confidence limit for the specificity which is no more than 3% lower than the estimate of specificity have been calculated for NNE values of 6, 7 and 8, for 5% and 2% true positives in the population, based on Table 1. Table 2 shows the results.

Table 2: Numbers of true positive and true negative lesions required for protocol HS-MAV-002
The number of true negative lesions examined in this study will be 654. Therefore at anticipated prevalence, total number of lesions recruited to the study should be less than 700.

The result of biopsy for each lesion will not be known until after the lesion has been included in the study. Therefore lesions will be added to the study until the required number of true negatives has been included. The resulting true positives will be used to estimate the sensitivity as a secondary endpoint.

### Data management and analysis

The Clinical Record Forms (CRFs) must be completed, signed and dated by the Investigator or an authorised member of staff prospectively. The completed originals will be collected by the trials co-ordinator and held in the site file as source documents. It is the responsibility of the Investigator to ensure that CRFs have been completed correctly and that the data are accurate. Entries should be made in ballpoint pen and should be legible. Any errors should be crossed out with a single stroke, the correction inserted and the change initialled and dated. All missing and ambiguous data will be queried. The CRF may be amended as appropriate; this will not constitute a protocol amendment. The revised CRF should be used by all participating sites with immediate effect.

The data will be transferred anonymously to a password –secured electronic database. All patients will be pseudo-anonymised. Data will be stored in databases at Skin Care Network, and any copies to be taken off site (for example for statistical analysis or for analysis by the equipment provider) will be anonymised and will be protected by encryption and password. Access will be restricted to medical and research personnel, and appropriate support personnel. Specific trial information will be restricted to Investigators and collaborators. The trial co-ordinator will be responsible for the daily administration of the database.

An initial interim analysis of the data will be planned after 25 patients to ensure the RCM images are of sufficient quality to continue and complete the study. Data validation will be co-ordinated under the supervision of the trial statistician once the recruitment target has been reached. The final analysis and publication of results will be undertaken after all patients have been recruited. The accrual period is estimated to be 12 months but will be continued until sufficient numbers are obtained for the study to reach significance. Once the dataset is complete, assessment of the RCM images by the blinded investigators will take place to allow statistical analysis of the primary and secondary endpoints, namely specificity, sensitivity and kappa statistics. Analysis of the final dataset is expected to take place within 6 months of completion of accrual. Publication is expected within 12 months of completing the trial.
Ethical Issues

The study proposal is subject to approval by the appropriate Ethics Committee and the host organisation’s Medical Advisory Committee (MAC), and will adhere to Good Clinical Practice Guidelines. The study will be conducted according to the principles of the Declaration of Helsinki and in accordance with the Medical research Involving Human Subjects Act (WMO).

Amendments

Amendments are changes made to the research after a favourable opinion by the accredited Ethics Committees has been given. All amendments will be notified to the Ethics Committees that gave a favourable opinion.

A ‘substantial amendment’ is defined as an amendment to the terms of the Ethics Committee(s) application, or to the protocol or any other supporting documentation, that is likely to affect to a significant degree:

- the safety or physical or mental integrity of the subjects of the trial;
- the scientific value of the trial;
- the conduct or management of the trial; or
- the quality or safety of any intervention used in the trial.

All substantial amendments will be notified to the Ethics Committees and to the competent authority.

Non-substantial amendments will not be notified to the accredited Ethics Committees and the competent authority, but will be recorded and filed by the sponsor.

Annual Progress Report

The sponsor/investigator will submit a summary of the progress of the trial to the accredited Ethics Committee once a year. Information will be provided on the date of inclusion of the first subject, numbers of subjects included and numbers of subjects that have completed the trial, serious adverse events/serious adverse reactions, other problems, and amendments.

End of study report

The investigator will notify the accredited Ethics Committees and the competent authority of the end of the study within a period of 8 weeks. The end of the study is defined as the last patient’s last follow-up after 1 year.

In case the study is ended prematurely, the investigator will notify the accredited Ethics Committees, including the reasons for the premature termination. Within one year after the end of the study, the investigator/sponsor will submit a final study report with the results of the study, including any publications/abstracts of the study, to the accredited Ethics Committees and the Competent Authority.

Public disclosure and publication policy

The study documentation must be retained at all times in a secure and protected environment. This will ensure the integrity of the study data is maintained and protects patient confidentiality.

The CCMO (Central Committee on research involving Human subjects) statement according publication policy is obligatory for participants of the HS-MAV-002 Study and the study sponsor. The results of scientific research involving human subjects must be disclosed unreservedly.
avoidance of doubt, negative study results will be published. Further information on publication is outlined in the clinical trial agreement.

Registration of the HS-MAV-002 study will be completed following successful ethical approval.

Safety Considerations

In accordance to section 10, subsection 1, of the WMO, the investigator will inform the subjects and the reviewing accredited Ethical Committees if anything occurs, on the basis of which it appears that the disadvantages of participation may be significantly greater than was foreseen in the research proposal. The study will be suspended pending further review by the accredited Ethics Committees, except insofar as suspension would jeopardise the subjects' health. The investigator will take care that all subjects are kept informed.

Adverse and Serious Adverse Events (SAE)

The investigator must inform the Sponsor, within one working day by telephone or fax, of any serious adverse event. The investigator must also complete and forward a serious adverse event form within four calendar days to the MAC of Skin Care Network. The investigator will be asked to assess the serious adverse events causal relationship to the study device. All SAEs will be reported for up to 30 days post-biopsy and RCM scanning.

Adverse events are defined as any undesirable experience occurring to a subject during the study, whether or not considered related to the experimental treatment. All adverse events reported spontaneously by the subject or observed by the investigator or his staff will be recorded.

A serious adverse event is any untoward medical occurrence that:

- results in death;
- is life threatening (at the time of the event);
- requires hospitalisation or prolongation of existing inpatients' hospitalisation;
- results in persistent or significant disability or incapacity;
- is a congenital anomaly or birth defect;
- is a new event of the trial likely to affect the safety of the subjects, such as an unexpected outcome of an adverse reaction, lack of efficacy of an IMP used for the treatment of a life threatening disease, major safety finding from a newly completed animal study, etc.

SAEs that result in death or are life threatening should be reported expedited. The expedited reporting will occur not later than 7 days after the responsible investigator has first knowledge of the adverse reaction. This is for a preliminary report with another 8 days for completion of the report.

Follow-up of adverse events

All adverse events will be followed until they have abated, or until a stable situation has been reached. Depending on the event, follow up may require additional tests or medical procedures as indicated, and/or referral to the general physician or a medical specialist.

Data Safety Monitoring Board

Not applicable to this study

Sponsorship & Indemnity

This trial is sponsored by Skin Care Network Barnet Ltd. The trial is being coordinated by Skin Care Network. These offices do not hold insurance against claims for compensation for injury caused by participation in a clinical trial and they cannot offer any indemnity. There are no specific arrangements for compensation made in respect of any serious adverse events occurring though participation in the study, whether from listed side effects, or others yet unforeseen. Skin Care...
Network has a duty of care to patients receiving treatment, whether or not the patient is taking part in a clinical trial. Compensation is only available via Clinic and consultant medical indemnity policies and only in the event of proven clinical negligence.

Publication Policy

All presentations and publications, including abstracts, relating to or arising from, the trial must be authorised by the Trial Medical Advisory Committee and the Chief Investigator.

Serious adverse events (SAE)

SAEs that result in death or are life threatening should be reported expedited. The expedited reporting will occur not later than 7 days after the responsible investigator has first knowledge of the adverse reaction. This is for a preliminary report with another 8 days for completion of the report.

Follow-up of adverse events

All adverse events will be followed until they have abated, or until a stable situation has been reached. Depending on the event, follow up may require additional tests or medical procedures as indicated, and/or referral to the general physician or a medical specialist.

Data Safety Monitoring Board

Not applicable to this study

References: